Allergy Therapeutics (LON:AGY) Trading Down 7.8% – What’s Next?

Allergy Therapeutics plc (LON:AGY)’s share price dropped 7.8% during trading on Monday . The company traded as low as GBX 9.60 and last traded at GBX 10. Approximately 241,736 shares were traded during trading, a decline of 13% from the average daily volume of 278,121 shares. The stock had previously closed at GBX 10.85.

Allergy Therapeutics Stock Performance

The business has a 50 day moving average of GBX 10.58 and a 200 day moving average of GBX 10.53. The company has a market capitalization of £631.99 million, a P/E ratio of -10.29, a price-to-earnings-growth ratio of -30.70 and a beta of 0.91. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last announced its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. The firm had revenue of GBX 3,628 million for the quarter. On average, sell-side analysts predict that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.